Sunday, January 11, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Deutsche Bank Analyst Downgrades Grifols to Sell Rating Amid Growing Skepticism

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
Unlocking Value: The Economic Potential of Iron-Titanium-Vanadium Projects
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

On March 12, 2024, analyst Emmanuel Papadakis from Deutsche Bank made a bold move by downgrading Grifols (NASDAQ: GRFS) from a “Hold” to a “Sell” rating. This decision reflects a growing sentiment among analysts who are becoming increasingly skeptical of Grifols due to lackluster guidance and perceived issues with transparency and communication. As a result, the stock has taken a hit, with several firms following suit and adjusting their recommendations for the company.

GRFS Stock Price Drops 7.09% in Regular Trading Hours, Sees After-Hours Rebound

On March 12, 2024, GRFS stock experienced a significant drop in its price, closing at $6.29, which was a decrease of $0.48 or 7.09% from the previous market close. Despite the drop in price during regular trading hours, GRFS stock saw a slight increase of $0.11 in after-hours trading. This after-hours activity suggests that there may be some renewed interest or optimism in the stock, potentially leading to a rebound in the coming days. Investors and analysts will be closely monitoring the performance of GRFS stock in the coming days to see if the after-hours gain will be sustained and if the stock can recover from its recent decline.

GRFS Stock Performance Analysis: Revenue, Net Income, and EPS Decline in Q1 2024

On March 12, 2024, GRFS stock experienced a mixed performance based on the financial data provided. The total revenue for the company was $5.83 billion over the past year, but this represented a decrease of 4.22% compared to the previous year. In the first quarter of 2024, the total revenue further decreased to $1.43 billion, marking an 8.58% decline since the last quarter.

The net income for GRFS was $216.07 million over the past year, but this figure decreased by a significant 69.36% compared to the previous year. However, the net income held flat at $156.50 million in the first quarter of 2024, showing no change since the last quarter.

Earnings per share (EPS) for GRFS stood at $0.32 over the past year, which was a 69.23% decrease from the previous year. The EPS remained flat at $0.23 in the first quarter of 2024, showing no change compared to the last quarter.

Overall, the financial performance of GRFS stock on March 12, 2024, reflected a decline in total revenue, net income, and earnings per share compared to the previous year. However, the company managed to maintain its net income and EPS at the same level since the last quarter. Investors and analysts may closely monitor these financial indicators to assess the company’s future growth prospects and stock performance.

Tags: GRFS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Food Producers Stock Market Today

Product Recall Great Value Honey Roasted Cashews with Undeclared Coconut and Milk

Investment

Unveiling the Power of Convertible Notes: A New Avenue for Funding Innovation and Growth

Fur ban

The Rise of Ethical Consumerism: How Bans on Mink Fur Farming Impact Fashion Industry Economics

Recommended

Upcoming FDA Advisory Committee Meeting for Imetelstat A Groundbreaking Treatment for Malignant Stem Cells

2 years ago
Portillo's Stock

Leadership Turmoil Sends Portillo’s Shares to New Low

2 months ago
Dine Brands Global Stock

Dine Brands Stock Faces Potential Downturn

1 month ago
Intel Stock

US Government Considers Taking Equity Stake in Intel

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Alibaba’s Strategic Crossroads: Balancing AI Ambition Against Rising Costs

Vulcan Energy Shares Navigate Investor Reshuffle Amid Major Project Funding

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals

Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

Procter & Gamble Shares Approach a Critical Juncture

Trending

XRP Stock
Analysis

XRP Market Dynamics: Institutional Pause Meets Accumulation Surge

by Andreas Sommer
January 11, 2026
0

The XRP market is currently defined by a stark divergence in investor behavior. After a powerful rally...

Rocket Lab USA Stock

Rocket Lab’s Stock Momentum Continues Unabated in 2026

January 11, 2026
Eli Lilly Stock

Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances

January 11, 2026
Alibaba Stock

Alibaba’s Strategic Crossroads: Balancing AI Ambition Against Rising Costs

January 11, 2026
Vulcan Energy Stock

Vulcan Energy Shares Navigate Investor Reshuffle Amid Major Project Funding

January 11, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • XRP Market Dynamics: Institutional Pause Meets Accumulation Surge
  • Rocket Lab’s Stock Momentum Continues Unabated in 2026
  • Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com